Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Core Insights - Omega Therapeutics has published preclinical data demonstrating the efficacy of OTX-2002 in downregulating MYC gene expression and inhibiting tumor growth in hepatocellular carcinoma (HCC) models [1][3] - The OMEGA platform enables the design of programmable epigenomic mRNA medicines that can target and modulate gene expression, including historically undruggable targets [1][4] Group 1: OTX-2002 and Its Mechanism - OTX-2002 is a first-in-class epigenomic controller that downregulates MYC expression pre-transcriptionally through two distinct epigenetic modifications [2][3] - Treatment with OTX-2002 resulted in a rapid reduction of MYC mRNA and protein levels, decreased viability of HCC cell lines, and a dose-dependent reduction in tumor size [3][4] - The antitumor activity of OTX-2002 is synergistic when combined with tyrosine kinase inhibitors or immune checkpoint inhibitors [3] Group 2: OMEGA Platform and Its Potential - The OMEGA platform leverages advanced understanding of gene regulation and epigenetic mechanisms to create mRNA medicines that can precisely target gene expression [4][5] - Omega Therapeutics aims to revolutionize genomic medicine with a pipeline of therapeutic candidates addressing various diseases, including oncology and cardiometabolic conditions [6] Group 3: Clinical Evaluation - OTX-2002 is currently undergoing clinical evaluation in the Phase 1/2 MYCHELANGELO™ I trial for adult patients with HCC and other MYC-associated solid tumors [3]